Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens

Clinical Cancer Research

Volumn 3, Issue 6, 1997, Pages 849-854

  Wilcken, Nicholas R C ^a   Prall, Owen W J ^a   Musgrove, Elizabeth A ^a   Sutherland, Robert L ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CYCLIN D1; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RETINOBLASTOMA PROTEIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG RESISTANCE; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYUNSATURATED ALKAMIDES; PROTO-ONCOGENE PROTEINS; S PHASE; TAMOXIFEN; TUMOR CELLS, CULTURED; ZINC SULFATE;

EID: 0030964233     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wolf, D. M., and Jordan, V. C. William L. McGuire Memorial Symposium. Drug resistance to tamoxifen durina breast cancer therapy. Breast Cancer Res. Treat., 27: 27-40, 1993.
2. Sutherland, R. L., Green, M. D., Hall, R. E., Reddel, R. R., and Taylor. I. W. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur. J Cancer Clin. Oncol., 19: 615-621, 1983.
3. Taylor, I. W., Hodson, P. J., Green, M. D., and Sutherland, R. L. Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res., 43: 4007-4010, 1983.
4. Sherr, C. J. G1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
5. Fantl, V., Smith, R., Brookes, S., and Dickson, C. Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv., 18: 77-93, 1993.
6. Musgrove, E. A., Hamilton, J. A., Lee, C. S. L., Sweeney, K. J. E., Watts, C. K. W., and Sutherland, R. L. Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13: 3577-3587, 1993.
7. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem., 272: 10882-10894, 1997.
8. Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K. W., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-2133, 1993.
9. Bartkova, J., Lukas, J., Müller, H., Lützhøft, D., Strauss. M., and Bartek, J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer. 57: 353-361, 1994.
10. Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond.), 369: 669-671, 1994.
11. Watts, C. K. W., Brady, A., Sarcevic, B., deFazio, A., Musgrove, E. A., and Sutherland, R. L. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependem kinase activity and decreased rctinoblastoma protein phosphorylation. Mol. Endocrinol., 9: 1804-1813, 1995.
12. Daly, R. J., Hams, W. H., Wang, D. Y., and Darbre, P. D. Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth & Differ., 2: 457-464, 1991.
13. 1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA, 91: 8022-8026, 1994.
14. Musgrove, E. A., Sarcevic, B., and Sutherland, R. L. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB phosphorylation. J. Cell. Biochem., 60: 363-378, 1996.
15. Weinberg, R. A. The retinoblastoma protein and cell cycle control Cell. 81: 323-330, 1995.
16. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 339: 1-15, 71-85, 1992.
17. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Breast Cancer Trials Committee. Lancet, ii: 171-175, 1987.
18. Spataro, V., Price, K., Goldhirsch, A., Simoncini, E., Castiglione, M., Rudenstam, C-M., Collins, J., Lindtner, J., and Gelber, R. D. IBCS Group. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. Ann. Oncol., 3: 733-740, 1992.
19. Johnston, S. R., Saccani-Jotti, G., Smith, I. E., Salter, J., Newby, J., Coppen, M., Ebbs, S. R., and Dowsett, M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res., 55: 3331-3338, 1995.
20. Seshadri, R., Lee, C. S. L., Hui, R., McCaul, K., Horsfall, D. J., and Sutherland, R. L. Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin. Cancer Res., 2: 1177-1184, 1996.
21. Strauss, M., Lukas, J., and Bartek, J. Unrestricted cell cycling and cancer. Nat. Med., 7: 1245-1246, 1995.
22. Gillett, C., Smith, P., Gregory, W., Richards, M., Millis, R., and Peters, G. Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer, 69: 1-8, 1996.
23. Howell, A., DeFriend, D., Robertson, J., Blarney, R., and Walton, P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345: 29-30, 1995.